Selected article for: "african Vero green monkey kidney and Vero green monkey kidney"
Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals
  • Document date: 2020_4_17
    • ID: 1fgnfh62_26
    Snippet: Replication. One of the most efficient ways to identify antiviral candidates against an emergent virus, such as SARS-CoV-2, that can be rapidly evaluated in clinical trials is to repurpose clinically assessed drugs. Given the urgent need for therapeutics to treat SARS-CoV-2 infection, we developed a high-throughput assay to screen a comprehensive repurposing library. Vero E6 cells, kidney epithelial cells derived from an African green monkey, hav.....
    Document: Replication. One of the most efficient ways to identify antiviral candidates against an emergent virus, such as SARS-CoV-2, that can be rapidly evaluated in clinical trials is to repurpose clinically assessed drugs. Given the urgent need for therapeutics to treat SARS-CoV-2 infection, we developed a high-throughput assay to screen a comprehensive repurposing library. Vero E6 cells, kidney epithelial cells derived from an African green monkey, have been shown to be highly permissive to SARS-CoV-2 infection 42 and viral replication can be assessed through measurement of viral-induced cytopathic effects (CPE) 43 . A clinical isolate of the SARS-CoV-2 virus (SARS-CoV-2 author/funder. All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • african green monkey and clinical trial: 1
    • african green monkey and CPE cytopathic effect: 1, 2, 3, 4, 5, 6, 7, 8
    • african green monkey and cytopathic effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • african green monkey and epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • african green monkey and green monkey: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • african green monkey and high throughput: 1, 2
    • antiviral candidate and clinical trial: 1, 2, 3, 4, 5, 6
    • antiviral candidate and cytopathic effect: 1, 2, 3, 4
    • antiviral candidate and high throughput: 1, 2, 3, 4, 5, 6
    • antiviral candidate and high throughput assay: 1, 2, 3, 4, 5
    • antiviral candidate and high throughput assay develop: 1
    • clinical isolate and CPE cytopathic effect: 1
    • clinical isolate and cytopathic effect: 1, 2, 3, 4
    • clinical isolate and epithelial cell: 1, 2, 3
    • clinical isolate and green monkey: 1
    • clinical isolate and high throughput: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • clinical isolate and high throughput assay: 1, 2, 3
    • clinical trial and CPE cytopathic effect: 1, 2
    • clinical trial and cytopathic effect: 1, 2, 3, 4